## Diagnosis & Classification This patient has **lepromatous leprosy (LL)** — evidenced by high bacterial load (4+ AFB on slit-skin smear), widespread lesions, and intact sensation loss pattern consistent with advanced disease. ## Multidrug Therapy (MDT) for Lepromatous Leprosy **Key Point:** WHO-MDT for lepromatous leprosy consists of a 12-month regimen of three drugs: **rifampicin, dapsone, and clofazimine**. ### Role of Each Drug in MDT-LL | Drug | Role | Mechanism | Key Feature | |------|------|-----------|-------------| | **Rifampicin** | Backbone / first-line | Inhibits bacterial RNA polymerase | Bactericidal; most potent; renders patient non-infectious within 2 weeks | | **Dapsone** | Second agent | Inhibits PABA metabolism (sulfonamide) | Bacteriostatic; long half-life (~24 h) | | **Clofazimine** | Third agent | Generates reactive oxygen species | Bacteriostatic; slow-acting; anti-inflammatory; red-brown discoloration | **High-Yield:** Rifampicin is the **most potent antileprotic** and is the cornerstone of all MDT regimens (both paucibacillary and lepromatous). It is given as the **first-line drug** in MDT initiation. ## Why Rifampicin is the Drug of Choice 1. **Bactericidal activity** — kills *Mycobacterium leprae* directly 2. **Rapid reduction of bacterial load** — patient becomes non-infectious within 2 weeks 3. **Essential in all MDT regimens** — no alternative exists 4. **Prevents drug resistance** — used in combination to avoid monotherapy resistance **Clinical Pearl:** Rifampicin is given as a monthly supervised dose (600 mg) in WHO-MDT to ensure compliance and reduce pill burden. **Warning:** Do not use rifampicin monotherapy — this leads to rapid resistance. MDT with all three drugs is mandatory.
Sign up free to access AI-powered MCQ practice with detailed explanations and adaptive learning.